We have signed an agreement to license technology based on oncolytic Coxsackievirus, which has shown good efficacy and safety in animal testing. Now our task is to bring this technology to the market, providing access to patients with cancer.
Blog
We have signed an agreement to license technology based on oncolytic Coxsackievirus, which has shown good efficacy and safety in animal testing. Now our task is to bring this technology to the market, providing access to patients with cancer.